News Releases

Holding in Company - 2nd

Interim Results for 2024 - 23rd

Holding in Company - 11th

Holding in Company - 10th

Half Year Trading Update - 4th

Adoption of new share plans and grant of share options to directors and employees - 12th

TrueVue System awarded to an NHS Supply Chain Framework Agreement - 4th

AGM Investor Presentation - 9th

Result of Annual General Meeting - 8th

AGM Statement - 8th

Holdings in Company - 8th

Posting of Annual Report & Notice of Annual General Meeting - 8th

Annual Report and Accounts 2023 - 8th

Results for the year ended 31 December 2023 - 28th

Holdings in Company - 2nd

Total Voting Rights - 31st

Year-end trading update - 18th

Issue of equity - 18th

Director Appointment and Commercial Update - 4th

Interim Results For 2023 - 18th

Total Voting Rights - 31st

Holdings in Company - 2nd

Holdings in Company - 2nd

Completion of Fundraising and Capital Reorganisation, Director shareholdings and change to total voting rights - 2nd

Results of General Meeting - 1st

Results of REX Retail Offer - 24th

Extension of REX Retail Offer - 19th

Proposed Amended Articles of Association - 15th

Marked up Proposed Amended Articles of Association - 15th

General Meeting Form of Proxy - 15th

Placing, Subscription and Retail Offer, Capital Reorganisation and Notice of General Meeting Circular - 15th

REX Retail Offer Announcement - 14th

Placing, Subscription and Retail Offer, Capital Reorganisation and Notice of General Meeting Announcement - 14th

Release of new next generation TrueVue System in the UK and the EU - 10th

Half-Year trading update and potential equity fundraise - 6th

Suspension of shares - 26th

Holdings in Company - 19th

AGM Investor Presentation - 17th

Result of AGM - 17th

AGM statement - 17th

Total Voting Rights - 28th

New monitor launch date - 25th

Issue of equity - 11th

Results Presentation 2022 - 30th

Annual Report and Accounts 2022 - 30th

Results for the year ended 31 December 2022 RNS - 30th

Convertible loan notes repayment date extension - 27th

Year end trading update - 24th

Year end update - 22nd

Interim Results for 2022 - 20th

Completion of Nominated Adviser due diligence and change of broker - 14th

Half year trading update - 7th

AGM Investor Presentation - 18th

Result of AGM - 18th

AGM Statement - 18th

Change of Adviser - 28th

Annual Report and Accounts 2021 - 11th

Investor Presentation April 2022 - 7th

2021 Results RNS - 7th

Holdings in Company - 3rd

Grant of options - 17th

Successful completion of Subscription - 8th

New Contract Win - 26th

Issue of Equity - 12th

Pre-close statement - 11th

Innovate UK Smart Award - 20th

Interim Results for 2021 - 20th

Issue of equity - 22nd

Issue of equity / Directors’ shareholdings - 16th

Pre-close statement - 8th

Result of AGM - 28th

AGM Statement - 27th

Grant of options - 28th

Annual Report & Accounts 2020 - 22nd

2020 Results RNS - 22nd

Intention to publish results and hold the AGM - 13th

Director Dealing - 9th

Pre-close statement and Director Appointment - 20th

Holdings in Company - 5th

Holdings in Company - 24th

Successful completion of share issue and retirement of director - 21st

Investor update - 21st

Director Dealing - 23rd

Grant of options - 20th

Pre-close trading update - 30th

AGM Statement - 3rd

Pre-close statement and trading update - 22nd

Director Dealing - 18th

Exercise of Options - 13th

Exercise of Options - 27th

Finance Director Appointed - 20th

Exercise of Options - 14th

Exercise of Options - 18th

Innovate UK Smart Award Granted - 10th

Directorate change - 7th

Holdings in Company - 24th

Exercise of Options - 23rd

Interim Results - 23rd

Holdings in Company - 13th

Holdings in Company - 11th

Exercise of Options - 9th

Exercise of Options - 22nd

Pre-close trading update - 30th

Exercise of Options - 23rd

EDM+ Innovative Technology Contract from Vizient - 2nd

Holdings in Company - 4th

Chairman's Statement to Annual General Meeting - 22nd

Result of AGM - 22nd

Holdings in Company - 13th

Exercise of Options - 13th

Publication of Annual Report and Notification of Annual General Meeting - 1st

Results presentation 2018 - 25th

Results summary for year ended 31 December 2018 - 25th

Holdings in Company - 6th

Director Dealing - 5th

Exercise of Options - 29th

Pre-close statement and trading update - 25th

Change of Auditor - 26th

Interim Report - 24th

Notice of Results - 18th

Director Dealing - 28th

Director Dealing - 23rd

Grant of Options - 6th

Director PDMR Shareholding - 30th

Director/PDMR Shareholding - 27th

Shareholding(s) in Company - 27th

Pre-close Trading Update - 25th

2018 AGM Presentation - 20th

Chairman’s Statement to Annual General Meeting - 20th

Result of AGM - 20th

Directorate change Appointment of new CEO - 13th

Partial redemption of convertible loan note - 18th

Annual Report and Notification of AGM - 17th

Results Summary for the year ended 31 December 2017 - 9th

TrueVue Loops display launched on CardioQ-ODM+ platform - 9th

Notice of Results & FEDORA update - 25th

Notification of Major Interest in Shares - 7th

Deltex Medical’s Oesophageal Doppler Monitoring System reduces postoperative complications by 75 per cent - 1st

CardioQ ODM wins Paris Hospital System tender - 20th

Director dealing and issue of equity - 12th

Result of General Meeting - 9th

Result of Offer and Additional Allotment - 9th

General Meeting Form of Proxy - 24th

Placing, Subscription, Offer for Subscription and Loan Notes Circular - 24th

Posting of Circular - 24th

Result of oversubscribed Placing - 23rd

Fundraising announcement - 23rd

Major new US hospital account - 17th

Pre-close Trading update for the year ended 31 December 2017 - 17th

US Launch of TrueVue System - 24th

New US hospital account - 3rd

Share Options - 25th

Release and first sale of HD-ICG in France - 23rd

Deltex Medical Webinar - 8th

Deltex Medical Webinar - 8th

Interim Report 2017 - 1st

Notice of Results - 31st

Investor Event - 30th

Notification of Major Interest in Shares - 2nd

Notification of Major Interest in Shares - 28th

Notification of Major Interest in Shares - 27th

Trading update - 21st

Placing and Issue of Shares - 21st

Director/PDMR Shareholding - 13th

2017 AGM Presentation - 9th

Chairman’s Statement to the Annual General Meeting - 9th

First randomised trial in thoracic surgery published - 9th

Result of Annual General Meeting (AGM) - 9th

Deltex granted patent for its innovative Combined Blood Flow and Blood Pressure Monitor - 31st

Deltex releases non-invasive High Definition Impedance Cardiography module - 4th

Exercise of Options - 3rd

Publication of Annual Report & Accounts 2016 and Notice of Annual General Meeting - 3rd

Deltex Medical Group plc Annual Report & Accounts 2016 - 27th

Results Summary for the year ended 31 December 2016 - 27th

EU TruVue Grant - 27th

Results Presentation - 27th

Investor Open Day and Notice of Results - 20th

Exercise of Option - 4th

Notification of Major Interest in Shares - 28th

Grant of Options - 22nd

Share issues - 22nd

New monitor sales in the US and UK - 23rd

South Korean broadens ODM reimbursement - 25th

Trading update in respect of year ended 31 December 2016 - 18th

Two additional US platform programme accounts: 30 platform accounts milestone passed - 18th

Additional US Platform Programme Account - 30th

NHS Hospital Invests in ODM Equipment - 4th

Deltex Webinar 2015 Interim Results - 16th

Interim Results for the Six Months Ended 30 June 2016 - 8th

Results Presentation - 8th

Three New US Platform Programme Accounts - 8th

Deltex Medical Group Plc Growing in every country we’re focused on - 7th

Notification of Major Interest in Shares - 15th

Notification of Major Interest in Shares - 15th

Results from head to head trial presented Significantly better outcomes from ODM - 11th

Pre-close Trading Update - 8th

Share Subscription - 1st

Director PDMR Shareholding - 17th

Two new accounts added to US platform programme - 8th

Deltex Medical Group CEO Stunning results & Well positioned - 6th

Deltex Medical Group CEO Stunning results & Well positioned - 2nd

AGM Presentation - 12th

Chairman’s Statement to Annual General Meeting - 12th

Directors’ Shareholdings-Issue of equity - 12th

Result of Annual General Meeting - 12th

Two additional US accounts added to platform programme - 12th

Enhanced performance TruFlow probe launched in UK - 5th

Deltex Medical Group Plc Ewan Philips talks TruFlow, improvements and sales - 4th

Posting of Annual Report and Notice of AGM - 20th

Results Summary for the year ended 31 December 2015 - 12th

Two new US platform programme accounts opened and notice of results - 5th

Placing and Issue of Shares - 10th

Notification of Major Interest in Shares TR1 - 2nd

Result of the GM - 25th

Result of the Open Offer - 23rd

Placing, Loan Notes and Open Offer Circular - 8th

Posting of Circular Announcement - 6th

Fundraising Announcement - 3rd

New US platform account 18 opened - 27th

Trading update for the year ended 31 December 2015 and funding plans - 27th